Clinical Impact of Dyspnea after Ticagrelor Treatment and the Effect of Switching to Clopidogrel in Patients with Myocardial Infarction
Thrombosis and Haemostasis · 01.12.2024 · 124 (12) · 1152-1161
DOI: 10.1055/a-2299-4537 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Thrombosis and Haemostasis, erschienen am 01.12.2024. Verfasst von Sang Hyun Kim und 17 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiology, The Catholic University of Korea, Seoul St. Mary's Hospital, Seoul, Korea. Hauptthemen laut MEDLINE: Ticagrelor, Clopidogrel, Dyspnea, Myocardial Infarction. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 28 Literaturangaben. Gefördert von: ChongKunDang Pharm, Medtronic, Abbott, and Boston Scientific.
Abstract (Originalsprache)
Background
Dyspnea is frequent during ticagrelor-based dual antiplatelet therapy (DAPT) for acute myocardial infarction (AMI). However, its clinical characteristics or management strategy remains uncertain.
Methods
The study assessed 2,617 AMI patients from the Ticagrelor versus Clopidogrel in Stabilized Patients with AMI (TALOS-AMI) trial. Dyspnea during 1-month ticagrelor-based DAPT and following DAPT strategies with continued ticagrelor or de-escalation to clopidogrel from 1 to 12 months were evaluated for drug adherence, subsequent dyspnea, major adverse cardiovascular events (MACE), and bleeding events.
Results
Dyspnea was reported by 538 patients (20.6%) during 1 month of ticagrelor-based DAPT. Adherence to allocated DAPT over the study period was lower in the continued ticagrelor arm than the de-escalation to clopidogrel, particularly among the dyspneic population (81.1% vs. 91.5%, p < 0.001). Among ticagrelor-treated patients with dyspnea, those switched to clopidogrel at 1 month had a lower frequency of dyspnea at 3 months (34.3% vs. 51.7%, p < 0.001) and 6 months (25.5% vs. 38.4%, p = 0.002) than those continued with ticagrelor. In patients with dyspnea in their 1-month ticagrelor-based DAPT, de-escalation was not associated with increased MACE (1.3% vs. 3.9%, hazard ratio [HR]: 0.31, 95% confidence interval [CI]: 0.08–1.11, p = 0.07) or clinically relevant bleeding (3.2% vs. 6.2%, HR: 0.51, 95% CI: 0.22–1.19, p = 0.12) at 1 year.
Conclusion
Dyspnea is a common side effect among ticagrelor-based DAPTs in AMI patients. Switching from ticagrelor to clopidogrel after 1 month in AMI patients may provide a reasonable option to alleviate subsequent dyspnea in ticagrelor-relevant dyspneic patients, without increasing the risk of ischemic events (NCT02018055).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Cardiology, The Catholic University of Korea, Seoul St. Mary's Hospital, Seoul, Korea.
- Division of Cardiology, Department of Internal Medicine, The Armed Forces Capital Hospital, Seongnam, Korea.
- Division of Cardiology, The Catholic University of Korea, Incheon St. Mary's Hospital, Incheon, Korea.
- Division of Cardiology, The Catholic University of Korea, Uijeongbu St. Mary's Hospital, Uijeongbu, Korea.
- Division of Cardiology, The Catholic University of Korea, St. Vincent's Hospital, Suwon, Korea.
- Division of Cardiology, The Catholic University of Korea, Daejeon St. Mary's Hospital, Daejeon, Korea.
ORCID-Profile: Sang Hyun Kim, Eun Ho Choo
Förderung
- ChongKunDang Pharm, Medtronic, Abbott, and Boston Scientific
Zitieren
APA
Kim, S. H., Shin, S., Choo, E. H., Choi, I. J., Lim, S., Moon, D., Kim, C. J., Park, M. W., Kim, M. C., Hwang, B. H., Lee, K. Y., Choi, Y. S., Kim, H. Y., Yoo, K. D., Jeon, D. S., Ahn, Y., Chang, K., & TALOS-AMI investigators (2024). Clinical Impact of Dyspnea after Ticagrelor Treatment and the Effect of Switching to Clopidogrel in Patients with Myocardial Infarction. Thrombosis and Haemostasis, 124(12), 1152-1161. https://doi.org/10.1055/a-2299-4537
Vancouver
Kim SH, Shin S, Choo EH, Choi IJ, Lim S, Moon D, et al. Clinical Impact of Dyspnea after Ticagrelor Treatment and the Effect of Switching to Clopidogrel in Patients with Myocardial Infarction. Thrombosis and Haemostasis. 2024;124(12):1152-1161. doi:10.1055/a-2299-4537
BibTeX
@article{Kim2024,
author = {Kim, Sang Hyun and Shin, Sanghoon and Choo, Eun Ho and Choi, Ik Jun and Lim, Sungmin and Moon, Donggyu and Kim, Chan Joon and Park, Mahn-Won and Kim, Min Chul and Hwang, Byung-Hee and Lee, Kwan Yong and Choi, Yun Seok and Kim, Hee-Yeol and Yoo, Ki-Dong and Jeon, Doo Soo and Ahn, Youngkeun and Chang, Kiyuk and TALOS-AMI investigators, TALOS-AMI investigators},
title = {Clinical Impact of Dyspnea after Ticagrelor Treatment and the Effect of Switching to Clopidogrel in Patients with Myocardial Infarction},
journal = {Thrombosis and Haemostasis},
year = {2024},
volume = {124},
number = {12},
pages = {1152--1161},
doi = {10.1055/a-2299-4537}
}
EUVIMED